Our preclinical trials confirm that the triple therapy (LOX inhibition + CLOCK-OLFML3 axis blockade + anti-PD1 therapy) leads to disease eradication in more than 60% of GBM-bearing mice. This evidence concerns the gene LOX and glioblastoma.